X

Legal Notices

Disclaimer

ADVERTISING MATERIAL
The material contained on this Web site is provided for informational purposes only and does not constitute legal advice. The publication and receipt of any information contained on this Web site does not create an attorney-client relationship with Barash Law LLC or with any of our attorneys. Readers should not act upon any information on this site without seeking professional legal counsel. While the information on this Web site is maintained and periodically updated for accuracy, this information may contain omissions or errors for which we disclaim any and all liability.

Privacy Statement

Barash Law LLC does not collect identifying information from visitors to its Web site unless the information is provided by the visitor or the visitor's internet browser. We will only respond to direct inquiries, and will use information collected from internet browsers for the sole purpose of monitoring Web site usage. We do not share Web site data with outside third-parties. Barash Law LLC is not responsible for the privacy practices or content of any links to other Web sites contained in our Firm’s Web site. 

If you have any questions or concerns regarding this Privacy Statement, please contact us at info@ebarashlaw.com

Moving in the Right Direction: Cocrystals and the FDA

Read More

Using Solid Form Patents to Protect Pharmaceutical Products — Part I

Read More

Using Solid Form Patents to Protect Pharmaceutical Products — Part II

Read More

NEWS & EVENTS

EVENTS
IP Watchdog Panel Discussion:
Crystalline/Solid Form Patents in the Life Sciences: Issues in Prosecution and Litigation
May 18th, 2021
12:00-1:30PM ET
In December of 2020, IPWatchdog hosted a webinar discussing the use of and interest in solid-form patents in the pharmaceutical industry. There were many questions during the webinar, and many follow-up inquiries on the “nuts and bolts” of these patents. Issues including prosecution, claim drafting, novelty, obviousness, enablement, non-species claims in a crystalline-form context, claim interpretation and proving infringement. This follow-on webinar  will dive deeper into these questions from a US-based perspective, and which will also compare and contrast these issues with elements of EU law. Panelists will discuss both court decisions as well as opinions from the USPTO (PTAB) and the EPO.
Register
EVENTS
Pharmalytical Summit 2021: A Virtual Forum presented by Rigaku
Using Solid Form IP to Protect Crucial Pharmaceutical Assets
May 26th, 2021
11:00AM ET
‍
When medicinal chemists create a new chemical entity, the solid form is rarely optimized because the initial focus is on activity and not drug delivery. As the NCE program matures, however, manufacturing, supply, and drug delivery become increasingly important. These other aspects of drug development present opportunities for patenting and creating value. These and other factors are often dependent on the solid-state structure of the entity. This webinar will discuss some of those opportunities and how resulting IP can be used to protect and leverage the final drug product estate.
Register

QUESTIONS ANSWERED

What is a solid form?

A solid form is the solid representation of a chemical compound.  Examples include polymorphs, salts, solvates, hydrates, cocrystals, and amorphous solids.

Read More
Why patent solid forms?

Solid forms are compositions of matter and Orange-Book listable as drug substance.  When the science is right, patenting follows.

Read More
How do you patent a solid form?

The same rules apply to solid forms as to any other inventions.  Careful attention should be paid to the kinds and quality of data used in solid form patents.

Read More

WHAT WE DO

pharmaceutical patents

Orange-Book Listable Patents Add Value

deals


Intellectual Property as Deal Currency

ip strategy and execution

A Strategy Requires a Realistic Plan

in-house
counsel

Legal Functionality as a Business Driver
© 2016 Barash Law LLC
Contact Us
Legal Notices